Bioactive lipids derived from arachidonic acid metabolism in different types of renal replacement therapy

Joanna Stępniewska; Barbara Dołęgowska; Kamila Puchałowicz; Edyta Gołembiewska; Kazimierz Ciechanowski

doi:10.1016/j.chemphyslip.2017.05.003

Bioactive lipids derived from arachidonic acid metabolism in different types of renal replacement therapy

Chem Phys Lipids. 2017 Aug:206:71-77. doi: 10.1016/j.chemphyslip.2017.05.003. Epub 2017 May 19.

Authors

Joanna Stępniewska¹, Barbara Dołęgowska², Kamila Puchałowicz³, Edyta Gołembiewska⁴, Kazimierz Ciechanowski⁴

Affiliations

¹ Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland. Electronic address: asia_stepniewska@wp.pl.
² Department of Laboratory Medicine, Pomeranian Medical University, Szczecin, Poland.
³ Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Poland.
⁴ Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.

PMID: 28533146
DOI: 10.1016/j.chemphyslip.2017.05.003

Abstract

Introduction: Metabolism and plasma concentration of lipids and lipid-derived compounds play an important role in kidney physiology and pathological processes. The component of membrane phospholipids - arachidonic acid (AA) and its active derivatives - eicosanoids are involved in the development of hypertension, diabetes, inflammation and may contribute to progression of chronic kidney disease (CKD). The purpose of the study was to determine, whether the type of renal replacement therapy has an effect on eicosanoids metabolism.

Materials and methods: The study included 145 patients with CKD: on conservative treatment (n=68), on peritoneal dialysis (PD) (n=23) and undergoing chronic haemodialysis (HD) (n=54). The concentrations of TXB₂, 20-HETE, 8-epi-PGF_2α in platelet poor plasma (PPP) were determined using the ELISA method and 5-HETE, 12-HETE, 15-HETE were measured using the RP-HPLC.

Results: The concentrations of TXB₂ in HD group, both before (2.28±0.72ng/mL) and after (1.49±0.63ng/mL) haemodialysis treatment differed significantly from PD group (57.76±6.13ng/mL). Haemodialysis session led to the significant decrease in TXB₂ plasma concentration (p=0.046). 20-HETE concentrations in HD group (113.55±107.54pg/mL and 199.54±142.98pg/mL before and after haemodialysis, respectively) were significantly higher than in CKD 3-5 group (8.96±12.66pg/mL) and PD group (47.78±34.07pg/mL). The highest concentration of 12-HETE was obtained in PD patients (3.58±3.99ng/mL) and differed significantly from HD group after haemodialysis (0.97±0.28ng/mL) and CKD3-5 group (1.06±0.52ng/mL). The concentrations of 5-HETE, 15-HETE and 8-epi-PGF_2α-III did not differ significantly among examined groups.

Conclusions: The concentrations of active AA metabolites depend on the mode of renal replacement therapy and are associated with intensity of oxidative stress. They might be considered as potential indicators of kidney damage.

Keywords: Active eicosanoids; Arachidonic acid; Chronic kidney disease; Haemodialysis; Oxidative stress; Peritoneal dialysis; Platelets.

MeSH terms

Aged
Arachidonic Acid / metabolism*
Eicosanoids / metabolism*
Female
Humans
Male
Middle Aged
Renal Dialysis*

Substances

Eicosanoids
Arachidonic Acid